BACKGROUND: It is well known that cyclophosphamide (Cy) treatment before sensitization paradoxically enhances rather than suppresses contact hypersensitivity (CH) reactions. In fact, Cy-treated mice developed a significant (p < 0.05) increase of the CH reactions to 2,4,6-trinitro-1-chrolobenzene (TNCB) in comparison with untreated mice. OBJECTIVE: In order to examine whether the target cells of Cy in the immuno-augmentative effect are CD25(+) CD4(+) regulatory T cells or not, we investigated effect of Cy treatment on CD25(+) CD4(+) T cells. METHOD: We examined Cy-treated CD25(+) CD4(+) T cells by flow cytometer and by inhibition assay on proliferation of CD25(-) CD4(+) T cells. RESULTS: Cy treatment remarkably reduced the number and percentage of CD25(+) CD4(+) T cells in the spleen and lymph nodes 3 and 5 days later. Moreover, CD25(+) CD4(+) T cells taken from the Cy-treated mice 3 days later showed the lower suppressive activity on proliferation of CD25(-) CD4(+) T cells, as compared to that from the untreated mice. Furthermore, transfer of CD25(+) CD4(+) T cells from untreated mice resulted in a significant decrease (p < 0.05) of the CH reactions enhanced by Cy treatment. CONCLUSION: These results indicate that enhancement of the CH reactions to TNCB by Cy treatment is attributed to the decrease in the number, percentage and the function of CD25(+) CD4(+) regulatory T cells.
BACKGROUND: It is well known that cyclophosphamide (Cy) treatment before sensitization paradoxically enhances rather than suppresses contact hypersensitivity (CH) reactions. In fact, Cy-treated mice developed a significant (p < 0.05) increase of the CH reactions to 2,4,6-trinitro-1-chrolobenzene (TNCB) in comparison with untreated mice. OBJECTIVE: In order to examine whether the target cells of Cy in the immuno-augmentative effect are CD25(+) CD4(+) regulatory T cells or not, we investigated effect of Cy treatment on CD25(+) CD4(+) T cells. METHOD: We examined Cy-treated CD25(+) CD4(+) T cells by flow cytometer and by inhibition assay on proliferation of CD25(-) CD4(+) T cells. RESULTS:Cy treatment remarkably reduced the number and percentage of CD25(+) CD4(+) T cells in the spleen and lymph nodes 3 and 5 days later. Moreover, CD25(+) CD4(+) T cells taken from the Cy-treated mice 3 days later showed the lower suppressive activity on proliferation of CD25(-) CD4(+) T cells, as compared to that from the untreated mice. Furthermore, transfer of CD25(+) CD4(+) T cells from untreated mice resulted in a significant decrease (p < 0.05) of the CH reactions enhanced by Cy treatment. CONCLUSION: These results indicate that enhancement of the CH reactions to TNCB by Cy treatment is attributed to the decrease in the number, percentage and the function of CD25(+) CD4(+) regulatory T cells.
Authors: Timothy Kottke; Jill Thompson; Rosa Maria Diaz; Jose Pulido; Candice Willmon; Matt Coffey; Peter Selby; Alan Melcher; Kevin Harrington; Richard G Vile Journal: Clin Cancer Res Date: 2009-01-15 Impact factor: 12.531
Authors: Maria A Thomas; Jacqueline F Spencer; Karoly Toth; John E Sagartz; Nancy J Phillips; William S M Wold Journal: Mol Ther Date: 2008-07-29 Impact factor: 11.454
Authors: Mohamed L Salem; Amir A Al-Khami; Sabry A El-Naggar; C Marcela Díaz-Montero; Yian Chen; David J Cole Journal: J Immunol Date: 2010-01-18 Impact factor: 5.422
Authors: Joris D Veltman; Margaretha E H Lambers; Menno van Nimwegen; Sanne de Jong; Rudi W Hendriks; Henk C Hoogsteden; Joachim G J V Aerts; Joost P J J Hegmans Journal: J Biomed Biotechnol Date: 2010-05-23
Authors: Ekaterina A Alyamkina; Valeriy P Nikolin; Nelly A Popova; Evgenia V Dolgova; Anastasia S Proskurina; Konstantin E Orishchenko; Yaroslav R Efremov; Elena R Chernykh; Alexandr A Ostanin; Sergey V Sidorov; Dmitriy M Ponomarenko; Stanislav N Zagrebelniy; Sergey S Bogachev; Mikhail A Shurdov Journal: Genet Vaccines Ther Date: 2010-11-01
Authors: Daniel Hirschhorn-Cymerman; Gabrielle A Rizzuto; Taha Merghoub; Adam D Cohen; Francesca Avogadri; Alexander M Lesokhin; Andrew D Weinberg; Jedd D Wolchok; Alan N Houghton Journal: J Exp Med Date: 2009-05-04 Impact factor: 14.307
Authors: Ekaterina A Alyamkina; Evgenia V Dolgova; Anastasia S Likhacheva; Vladimir A Rogachev; Tamara E Sebeleva; Valeriy P Nikolin; Nelly A Popova; Konstantin E Orishchenko; Dmitriy N Strunkin; Elena R Chernykh; Stanislav N Zagrebelniy; Sergei S Bogachev; Mikhail A Shurdov Journal: Genet Vaccines Ther Date: 2009-08-14